NewLimit is a biotechnology company working to radically extend human healthspan. We're developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/16/25 | $130,000,000 | Series B |
Dimension Capital Elad Gil Founders Fund Fred Ehrsam Garry Tan Human Capital Joe Lonsdale Josh Kushner Khosla Ventures Kleiner Perkins Caufield and Byers  | undisclosed |
